Yoshida Masayoshi, Ando Shin-Ichi, Kodama Kazuhisa, Ebihara Kie, Tanaka Kaoru, Hayashi Atsumi, Taguchi Eiji, Kadokami Toshiaki, Nakao Kouichi, Sakamoto Tomohiro
Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan.
Sleep Apnea Center, Kyushu University Hospital, Fukuoka, Japan; Cardiology Division Saiseikai Futsukaichi Hospital, Chikushino, Japan.
Int J Cardiol. 2017 Jul 1;238:173-176. doi: 10.1016/j.ijcard.2017.02.075. Epub 2017 Feb 22.
Adaptive servo-ventilation (ASV) therapy is a recently developed non-pharmacological therapy that has been reported to improve cardiac function and survival in patients with severe congestive heart failure (CHF). However, a recent large randomized study suggested that ASV does not improve survival in patients with reduced ejection fraction. It remains unclear whether ASV treatment can reduce the hospitalization rate of CHF patients. We thus examined the frequency of hospital admission before and after initiation of ASV therapy in patients with CHF.
Hospitalization frequencies during the 12months before and 12months after initiation of ASV therapy (24 consecutive months) were retrospectively compared in 44 consecutive patients with severe CHF. The admission frequency decreased from 1.9±1.4 admissions in the 12months before ASV to 1.1±1.6 admissions in the 12months after ASV initiation (P<0.001). The decrease tended to be greater in those patients with more frequent hospitalizations before ASV initiation.
ASV therapy reduces hospital admissions in patients with severe CHF who are receiving maximum medical treatment.
适应性伺服通气（ASV）疗法是一种最近开发的非药物疗法，据报道可改善重度充血性心力衰竭（CHF）患者的心脏功能和生存率。然而，最近一项大型随机研究表明，ASV并不能提高射血分数降低患者的生存率。ASV治疗是否能降低CHF患者的住院率仍不清楚。因此，我们研究了CHF患者开始ASV治疗前后的住院频率。
对44例连续的重度CHF患者进行回顾性比较，比较ASV治疗开始前12个月和开始后12个月（连续24个月）的住院频率。住院频率从ASV治疗前12个月的1.9±1.4次入院降至ASV开始后12个月的1.1±1.6次入院（P<0.001）。在ASV治疗开始前住院频率较高的患者中，下降趋势往往更大。
ASV疗法可减少接受最大程度药物治疗的重度CHF患者的住院次数。
